ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Avidity-Based Capture of PD-L1-Expressing Exosomes via Dendrimer-Peptide Conjugates: A Nanoengineered Platform for Enhanced Prediction of Immunotherapy Response.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Article
- Intracellular PD-L1: Functions, Regulation, and Therapeutic Implications.International journal of biological sciences · 2026Review
- Advances in immunotherapy for thyroid malignancies: from molecular targets to clinical outcomes.Frontiers in medicine · 2026Review
- Avidity-Based Capture of PD-L1-Expressing Exosomes via Dendrimer-Peptide Conjugates: A Nanoengineered Platform for Enhanced Prediction of Immunotherapy Response.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
A major challenge in immunotherapy is the inability to reliably predict patient responses due to the lack of robust biomarkers. Programmed cell death-ligand 1 (PD-L1)-expressing exosomes represent a promising biomarker candidate; however, existing detection platforms lack the sensitivity and specificity required for clinical translation. It is hypothesized that an avidity-based capture strategy utilizing dendrimer-mediated multivalent binding will effectively enhance molecular avidity and improve the selective capture of PD-L1-expressing exosomes. Supporting this hypothesis, atomic force microscopy (AFM) revealed that dendrimer-peptide conjugates synthesized using generation 7 poly(amidoamine) dendrimers (G7-pPDL1) exhibited ≈2.48-fold higher binding avidity than conventional anti-PD-L1 antibodies (aPD-L1), attributed to multivalent interactions. This increased avidity led to enhanced in vitro specificity and enabled 1.55-fold greater sensitivity in capturing PD-L1-expressing exosomes, compared to aPD-L1. Clinical validation using serum samples from patients undergoing immune checkpoint inhibitor therapy demonstrated that PD-L1-expressing exosomes captured using the G7-pPD-L1 surface more accurately predicted treatment response and outperformed tissue-based PD-L1 scoring in prognostic value. Additionally, this platform is compatible with existing biosensing technologies and enables real-time exosome detection with a limit of detection as low as 9.6 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.